Skip to main content

Temporal control of the termination of neurogenesis

NINDS - National Institute of Neurological Disorders and Stroke

open
Open

About This Grant

Abstract. Why can’t adult mammalian brains fully regenerate after damage or degeneration? The primary reason lies in their limited capacity for neurogenesis. In adult mice, neurogenesis occurs slowly and only in the olfactory bulb and the hippocampus. This is a stark difference from embryonic stages, where rapid neurogenesis occurs throughout all brain regions. The source behind this rapid embryonic neurogenesis is the embryonic neural stem cells (NSCs), also known as radial glia. Shortly after birth, however, these cells “disappear” by retracting their long radial processes and transforming into other cell types. Consequently, neurogenesis is terminated throughout the majority of the central nervous system (CNS). Similar to mice, radial glia in humans rapidly generate neurons during embryonic development and disappear postnatally, leading to the termination of neurogenesis. How do NSCs keep time and shut down neurogenesis on a predictable schedule? What is the molecular logic underlying the disappearance of radial glia? These questions remain unanswered. Temporal control of postnatal termination of neurogenesis is one of the major knowledge gaps in brain development and this lack of understanding presents a significant bottleneck in stem cell therapy development. Currently, experimental NSC transplantation therapies fail to generate sufficient numbers of neurons to significantly improve disease outcome and, consequently, there is no Food and Drug Administration-approved NSC therapy yet. Investigating the regulation of the termination of neurogenesis in the developing brain will reveal novel molecular targets for maintaining or expanding the duration of neurogenesis of transplanted NSCs, which can be targeted for the development of next generation NSC therapies. NSC therapies with enhanced neurogenesis capacity could transform the treatment landscape of a broad range of neurological disorders including stroke and neurodegeneration. Here, we propose to investigate the temporal control of the postnatal termination of neurogenesis and the disappearance of embryonic radial glia. A serendipitous discovery led us to study the role of PR-domain containing 16 (Prdm16), a histone methyltransferase, in postnatal NSCs. Our preliminary studies show that genetic deletion of Prdm16 from NSCs leads to the persistence of radial glia in the adult NSC niche and prolonged postnatal neurogenesis in the cerebral cortex. Based on these findings, we hypothesize that Prdm16 promotes the postnatal disappearance of embryonic radial glia and the termination of cortical neurogenesis. In Aim 1, we will determine the role of Prdm16 in regulating the fate and function of quiescent and activated NSCs. In Aim 2, we will identify the downstream mechanisms through which Prdm16 regulates the postnatal disappearance of embryonic radial glia and neurogenesis termination. In Aim 3, we will target the Prdm16-Vcam1 pathway to promote post-stroke neurogenesis.

Grant Summary

Temporal control of the termination of neurogenesis is a NINDS - National Institute of Neurological Disorders and Stroke grant providing up to $639K for university, nonprofit, healthcare org. Applications are due 2031-07-31 (open). Check eligibility and apply with FindGrants.

Not quite the right fit?

Search 9,000+ open grants, or get matches ranked for your organization — free.

Focus Areas

health research

Eligibility

universitynonprofithealthcare org

How to Apply

Funding Range

Up to $639K

Deadline

2031-07-31

Complexity
High
  1. 1Confirm your organization is eligible for Temporal control of the termination of neurogenesis from NINDS - National Institute of Neurological Disorders and Stroke, checking organization type, location, and any population or project requirements.
  2. 2Gather the required documents and information, including your organization details, project plan, and budget figures.
  3. 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
  4. 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NINDS - National Institute of Neurological Disorders and Stroke before the deadline.
This record is a past award, contract, or funder profile — useful for research, but not an open grant application. Check the original source for current opportunities from this funder.

Don't want to draft it yourself?

We'll draft the complete application against NINDS - National Institute of Neurological Disorders and Stroke's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.

AI Requirement Analysis

Detailed requirements not yet analyzed

Have the NOFO? Paste it below for AI-powered requirement analysis.

0 characters (min 50)

Temporal control of the termination of neurogenesis: Frequently Asked Questions

Who is eligible for the Temporal control of the termination of neurogenesis?

Temporal control of the termination of neurogenesis is offered by NINDS - National Institute of Neurological Disorders and Stroke and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.

How much funding does the Temporal control of the termination of neurogenesis provide?

Temporal control of the termination of neurogenesis provides up to $639K per award from NINDS - National Institute of Neurological Disorders and Stroke. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.

When is the Temporal control of the termination of neurogenesis deadline?

Applications for Temporal control of the termination of neurogenesis are due 2031-07-31 (open). Because deadlines can change, verify the date with the funder, NINDS - National Institute of Neurological Disorders and Stroke, and give yourself enough time to prepare a complete, competitive application before the close date.

How do you apply for the Temporal control of the termination of neurogenesis?

To apply for Temporal control of the termination of neurogenesis, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NINDS - National Institute of Neurological Disorders and Stroke.